Geron to Announce Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022

Rhea-AI Summary

Geron Corporation (NASDAQ: GERN) will release its fourth quarter and full year 2021 financial results after market close on March 10, 2022. A conference call will be held at 4:30 p.m. ET on the same day to discuss the results and upcoming milestones. Investors can access the press release on the company’s website. Geron is focused on developing imetelstat, a telomerase inhibitor, for hematologic malignancies, with ongoing Phase 3 clinical trials for lower risk myelodysplastic syndromes and refractory myelofibrosis.

Positive

• Geron is advancing its clinical pipeline with two Phase 3 trials, potentially enhancing future revenue streams.
• The conference call allows investors to engage directly with management regarding future milestones.

Negative

• None.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN) today announced that it will release its fourth quarter and full year 2021 financial results after the market closes on Thursday, March 10, 2022 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as upcoming milestones at 4:30 p.m. ET the same day.

A live webcast of the conference call and related presentation will be available on the Company’s website at www.geron.com/investors/events. An archive of the webcast will be available on the Company’s website for 30 days.

Participants may access the webcast by registering online using the following link, https://conferencingportals.com/event/SmvlMvWL. Participants that are unable to register online can access the conference call via telephone by dialing domestically +1 (888) 330-2434 or internationally +1 (240) 789-2725. The conference ID is 67335.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis. For more information about Geron, visit www.geron.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220303005990/en/

Olivia Bloom

Chief Financial Officer

investor@geron.com

media@geron.com

Source: Geron Corporation

FAQ

When will Geron Corporation release its financial results?

Geron Corporation will release its financial results on March 10, 2022, after market close.

What time is the Geron Corporation conference call?

The conference call will take place at 4:30 p.m. ET on March 10, 2022.

Where can I access Geron's financial results?

The financial results will be available on Geron's investor relations website at www.geron.com/investors.

What are the ongoing clinical trials for Geron Corporation?

Geron is conducting two Phase 3 clinical trials: IMerge for lower risk myelodysplastic syndromes and IMpactMF for refractory myelofibrosis.